Compound Sample Clauses

Compound. Appendix 2 Patents Country Patent Type Status App No. Filing Date Title A.R.I.P.O. Compound Filed AP/P/2021/013602 06-Aug-2021 Nitrile-Containing Antiviral Compounds Algeria Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Argentina Compound Filed P210102205 06-Aug-2021 Nitrile-Containing Antiviral Compounds Aruba Compound Filed Awaiting 06-Aug-2021 Nitrile-Containing Antiviral Compounds Australia Compound Filed 2021266232 06-Aug-2021 Nitrile-Containing Antiviral Compounds Bahamas Compound Docketed Nitrile-Containing Antiviral Compounds Bahrain Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Bangladesh Compound Filed 248/2021 08-Aug-2021 Nitrile-Containing Antiviral Compounds Barbados Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Bolivia Compound Filed SP-000165-2021 09-Aug-2021 Nitrile-Containing Antiviral Compounds Brazil Compound Filed BR112021022419-0 06-Aug-2021 Nitrile-Containing Antiviral Compounds Canada Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Chile Compound Filed 202102965 06-Aug-2021 Nitrile-Containing Antiviral Compounds China P.R. Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Colombia Compound Filed NC2021/0015067 06-Aug-2021 Nitrile-Containing Antiviral Compounds Costa Rica Compound Filed 2021-0558 06-Aug-2021 Nitrile-Containing Antiviral Compounds Cuba Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Dominican Republic Compound Filed P2021-0232 06-Aug-2021 Nitrile-Containing Antiviral Compounds Ecuador Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Egypt Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds El Salvador Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Eurasian Patent Convention Compound Filed 202192798 06-Aug-2021 Nitrile-Containing Antiviral Compounds European Patent Convention Compound Filed PCT/IB2021/057281 06-Aug-2021 Nitrile-Containing Antiviral Compounds Georgia Compound Filed 15794/1 06-Aug-2021 Nitrile-Containing Antiviral Compounds Guatemala Compound Filed A-2021-00229 06-Aug-2021 Nitrile-Containing Antiviral Compounds Honduras Compound Filed HN/P/2021/002695 06-Aug-2021 Nitrile-Containing Antiviral Compounds Hong Kong Compound Docketed Nitrile-Containing Antiviral Compounds India Compound Filed...
Compound. [***], with a structure described in greater detail in Schedule 1.21 of the Main Agreement, and all of its metabolites, prodrugs, isomers, enantiomers, esters, salts, hydrates, solvates and polymorphic forms.
Compound. For the purposes of this Section 1.77, the definition of each of “Development Costs” and “Development” shall be deemed to apply to Option Compounds mutatis mutandis as it applies to Licensed Compounds and Licensed Products (i.e., substituting “Option Compounds” for “Licensed Compounds” or “Licensed Products”).
Compound. (S)-N-(1-(2-((4-amino-3-nitrophenyl)amino)-6-propylpyrimidin-4-yl)pyrrolidin-3-yl)acetamide Schedule 1.10-1 Schedule 1.49 Form of Share Issuance Agreement SHARE ISSUANCE AGREEMENT THIS SHARE ISSUANCE AGREEMENT (this “Agreement”), is made as of August 19, 2020, by and between Yuhan Corporation (the “Yuhan”), and Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”).
Compound. Chemical Name: 24-(4-chlorobenzoyl) phenoxy 2-methyl-propanoic acid, 1-methyl ethyl ester Exhibit 1.24 Domain Names Fenoglide.com Exhibit 1.40 Inventory Lot Numbers Product 120mg / 90-count Lot # Cost per Bottle 1100149 [***] 1100150 [***] 1100742 [***] 1100743 [***] 1100744 [***] 40mg / 90-count Lot # Cost per Bottle 1101080 [***] 1100741 [***] 120mg / samples Lot # Cost per Bottle 1100746 [***] Compound Lot # Cost per Kilogram 2445115 [***] 2986098 [***] 3333605 [***] ***Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Exhibit 1.49
Compound. Naloxone or Option Compound and any metabolite, salt, ester, hydrate, anhydride, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, complexes, amorphous form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, isomer, tautomer, or optically active form of the foregoing. Option Compound *** REDACTED *** Field: Treatment or prevention of any disease, disorder, state, condition or malady in humans except *** REDACTED ***, provided that upon election of Lightlake in writing and payment of the Option Fee, the “Field” shall include the *** REDACTED ***. The Option Fee shall mean *** REDACTED *** and agreement by Lightlake that by expansion of the Field to include *** REDACTED ***, that Products for *** REDACTED ***in the Territory using the Aegis IP Rights shall be subject to the same monetary obligations as other Products in the Field (i.e. *** REDACTED ***milestones, royalties under terms and conditions to be negotiated in good faith by the parties).
Compound. The term “Compound” shall mean an Antibody-drug conjugate directed at a Development Target, [***] (a) that is Covered by one (1) or more of the Patents Rights included in the HDPR IP Rights, HDPR IP Improvements or Joint IP Rights or (b) that is discovered, identified or developed through the use or application of HDPR Know-How.
Compound. Versicor shall present to the JLDC the results of its studies; on each Biosearch Lead Compound and all Optimized Compounds. After approval by the JMC of a Biosearch Lead Compound as an Optimized Compound, Biosearch shall conduct Animal Studies on such Optimized Compound.